Immunoglobulin heavy variable 3-23-expressing B-cell receptor (IGHV3-23 BCR)

The IGHV3-23-expressing B-cell receptor (BCR) is a transmembrane protein complex on the surface of B lymphocytes that incorporates the IGHV3-23 heavy chain variable region. IGHV3-23 is the most frequently utilized VH gene segment in the human peripheral B-cell repertoire, making it a cornerstone of the adaptive immune response against various pathogens (Source: PMID: 25108498). In clinical oncology, the mutational status of the IGHV3-23 gene is a critical prognostic biomarker for Chronic Lymphocytic Leukemia (CLL), where unmutated clones are typically associated with more aggressive disease progression and poorer survival outcomes (Source: PMID: 10506550). This receptor is also characterized by its unique interaction with B-cell superantigens, such as Staphylococcal Protein A (SpA), which binds to the VH3 framework region independently of the complementarity-determining regions, leading to non-specific B-cell activation or deletion (Source: PMID: 9529138). Therapeutic interest in this target focuses on the development of precision agents, including CAR-T cells and monoclonal antibodies, designed to selectively eliminate malignant or autoreactive B-cell clones while minimizing impact on the broader immune system. However, because IGHV3-23-expressing B cells constitute a large portion of the normal B-cell population, therapeutic targeting carries a significant risk of inducing profound and prolonged immunosuppression.

Other names

VH3-23 B-cell receptorIGHV3-23+ BCRDP-47-expressing BCRIGHV3-23 immunoglobulinVH3-23-expressing BCR

Selective binding to the VH3-23 domain of the B-cell receptor to modulate B-cell activity, induce antibody-dependent cellular cytotoxicity (ADCC), or trigger apoptosis in specific B-cell clones.